Citizens reiterates Market Outperform on Taysha Gene Therapies

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Citizens analyst Silvan Turkcan has reiterated a Market Outperform rating on Taysha Gene Therapies. The firm maintains a price target of $11.

powered bylight_fuzz_icon
44549900

*this image is generated using AI for illustrative purposes only.

Citizens analyst Silvan Turkcan has reaffirmed a Market Outperform rating on Taysha Gene Therapies. The firm maintains a price target of $11 for the stock.

The rating reiteration underscores the analyst's continued confidence in the company's performance prospects.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What upcoming clinical milestones could drive Taysha Gene Therapies' stock toward the $11 price target?

How might recent advancements in gene therapy impact Taysha's competitive positioning?

What are the potential regulatory hurdles that could affect Taysha's growth trajectory?

like16
dislike

Baird raises Taysha Gene Therapies price target to $15

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Baird analyst Jack Allen maintained an Outperform rating for Taysha Gene Therapies and raised the price target to $15 from $12, reflecting a more optimistic outlook on the stock's potential.

powered bylight_fuzz_icon
43780179

*this image is generated using AI for illustrative purposes only.

Baird analyst Jack Allen has maintained an Outperform rating for Taysha Gene Therapies, citing a revised valuation. The firm increased its price target for the company to $15, up from the previous target of $12.

Rating and Price Target Details

The decision to raise the price target reflects a more optimistic outlook on the stock's potential. The Outperform rating suggests that the stock is expected to perform better than the market average.

Metric Value
Rating Outperform
Previous Price Target $12
New Price Target $15
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors drove Baird to revise its valuation model for Taysha Gene Therapies?

How might this price target increase influence investor sentiment toward Taysha's stock?

What upcoming clinical trial results could further impact Taysha's stock performance?

like17
dislike

More News on Taysha Gene Therapies Inc